Identifying multiple sclerosis in linked administrative health data in Aotearoa New Zealand.

IF 1.3 Q2 MEDICINE, GENERAL & INTERNAL NEW ZEALAND MEDICAL JOURNAL Pub Date : 2025-03-28 DOI:10.26635/6965.6823
Natalia Boven, Deborah F Mason, Barry J Milne, Annemarei Ranta, Andrew Sporle, Lisa Underwood, Julie Winter-Smith, Vanessa Selak
{"title":"Identifying multiple sclerosis in linked administrative health data in Aotearoa New Zealand.","authors":"Natalia Boven, Deborah F Mason, Barry J Milne, Annemarei Ranta, Andrew Sporle, Lisa Underwood, Julie Winter-Smith, Vanessa Selak","doi":"10.26635/6965.6823","DOIUrl":null,"url":null,"abstract":"<p><strong>Aim: </strong>The 2006 New Zealand national multiple sclerosis (MS) prevalence study (NZMSPS) provided invaluable information about the prevalence of MS in Aotearoa and characteristics of people with this debilitating condition. This study aimed to update the NZMSPS by identifying people with MS using linked administrative health records.</p><p><strong>Methods: </strong>Cases of MS were identified from hospitalisation, pharmaceutical dispensing, needs assessments for older adults and disability support records between January 1988 and June 2022. MS prevalence was estimated, and characteristics described and compared by sub-groups.</p><p><strong>Results: </strong>A total of 7,890 people (73% female) with MS were identified across the study period. The estimated crude national prevalence of MS in 2022 was 96.6 per 100,000 (72.4 in 2006). MS prevalence exhibited a strong latitudinal gradient. Estimated age-adjusted prevalence was highest for Europeans (124.7 per 100,000), followed by Middle Eastern/Latin American/African (MELAA) (85.5), Māori (41.8), Asian (16.8) and Pacific peoples (11.1) ethnic groups.</p><p><strong>Conclusion: </strong>Characteristics of MS cases were broadly similar to previous research, excepting a greater estimated prevalence among Māori, and a lower relative estimated prevalence for Auckland than surrounding regions. Linked administrative health data can be used to identify people with MS in Aotearoa, providing a mechanism for further research.</p>","PeriodicalId":48086,"journal":{"name":"NEW ZEALAND MEDICAL JOURNAL","volume":"138 1612","pages":"71-82"},"PeriodicalIF":1.3000,"publicationDate":"2025-03-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"NEW ZEALAND MEDICAL JOURNAL","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.26635/6965.6823","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}
引用次数: 0

Abstract

Aim: The 2006 New Zealand national multiple sclerosis (MS) prevalence study (NZMSPS) provided invaluable information about the prevalence of MS in Aotearoa and characteristics of people with this debilitating condition. This study aimed to update the NZMSPS by identifying people with MS using linked administrative health records.

Methods: Cases of MS were identified from hospitalisation, pharmaceutical dispensing, needs assessments for older adults and disability support records between January 1988 and June 2022. MS prevalence was estimated, and characteristics described and compared by sub-groups.

Results: A total of 7,890 people (73% female) with MS were identified across the study period. The estimated crude national prevalence of MS in 2022 was 96.6 per 100,000 (72.4 in 2006). MS prevalence exhibited a strong latitudinal gradient. Estimated age-adjusted prevalence was highest for Europeans (124.7 per 100,000), followed by Middle Eastern/Latin American/African (MELAA) (85.5), Māori (41.8), Asian (16.8) and Pacific peoples (11.1) ethnic groups.

Conclusion: Characteristics of MS cases were broadly similar to previous research, excepting a greater estimated prevalence among Māori, and a lower relative estimated prevalence for Auckland than surrounding regions. Linked administrative health data can be used to identify people with MS in Aotearoa, providing a mechanism for further research.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
识别新西兰奥特罗阿相关行政卫生数据中的多发性硬化症。
目的:2006年新西兰国家多发性硬化症(MS)患病率研究(NZMSPS)提供了关于新西兰多发性硬化症患病率和患有这种衰弱疾病的人的特征的宝贵信息。本研究旨在通过使用关联的行政健康记录识别MS患者来更新NZMSPS。方法:从1988年1月至2022年6月期间的住院、配药、老年人需求评估和残疾支持记录中确定MS病例。估计多发性硬化症的患病率,并按亚组描述和比较其特征。结果:在整个研究期间,共有7890人(73%为女性)被确诊为多发性硬化症。估计2022年多发性硬化症的粗流行率为96.6 / 10万(2006年为72.4 / 10万)。MS患病率呈现较强的纬度梯度。估计年龄调整患病率最高的是欧洲人(每10万人中有124.7人),其次是中东/拉丁美洲/非洲(MELAA)(85.5人),Māori(41.8人),亚洲(16.8人)和太平洋民族(11.1人)。结论:MS病例的特征与之前的研究大致相似,除了Māori的估计患病率更高,奥克兰的相对估计患病率低于周边地区。关联的管理健康数据可用于识别奥特罗阿的多发性硬化症患者,为进一步研究提供机制。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
NEW ZEALAND MEDICAL JOURNAL
NEW ZEALAND MEDICAL JOURNAL MEDICINE, GENERAL & INTERNAL-
CiteScore
2.30
自引率
23.50%
发文量
229
期刊最新文献
Diagnoses of blood-borne viruses and other sexually transmitted infections in a sample of 356 sex workers attending a sexual health outreach clinic in Auckland over a two-year period. Evolving roles and workforce trends among nurse practitioners in Aotearoa New Zealand (2014-2022). Performance first: why the economic success of our nation is dependent on the health of our people and why privatisation by stealth won't fix New Zealand's health system. Ethnic differences in population-level intracerebral haemorrhage incidence in Aotearoa New Zealand: findings from three Auckland Regional Community Stroke cohorts. Addressing significant inequity.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1